| Literature DB >> 23717119 |
Hye-Bin Yeo1, Ho-Kyoung Yoon, Heon-Jeong Lee, Seung-Gul Kang, Ki-Young Jung, Leen Kim.
Abstract
Ginseng has a long history of use for health enhancement, and there is some evidence from animal studies that it has a beneficial effect on cognitive performance. The purpose of this study was to investigate the effect of Korean red ginseng on cognitive performance in humans. A total of 15 healthy young males with no psychiatric or cognitive problems were selected based on an interview with a board-certified psychiatrist. The subjects were randomly assigned to receive a daily dose of 4,500 mg red ginseng or placebo for a 2-week trial. There were 8 subjects in the red ginseng group and 7 subjects in the placebo group. All of the subjects were analyzed with the Vienna test system and a P300 event-related potential (ERP) test. There were no significant differences in the Vienna test system scores between the red ginseng group and the placebo group. In the event-related potential test, the C3 latency of the red ginseng group tended to decrease during the study period (p=0.005). After 2 wk, significant decreases were observed in the P300 latencies at Cz (p=0.008), C3 (p=0.005), C4 (p=0.002), and C mean (p=0.003) in the red ginseng group. Our results suggest that the decreased latency in ERP is associated with improved cognitive function. Further studies with a higher dosage of ginseng, a larger sample size, and a longer follow-up period are necessary to confirm the clinical efficacy of Korean red ginseng.Entities:
Keywords: Cognitive and motor function; Evoked potentials; Korean red ginseng; Panax ginseng; Vienna test system
Year: 2012 PMID: 23717119 PMCID: PMC3659585 DOI: 10.5142/jgr.2012.36.2.190
Source DB: PubMed Journal: J Ginseng Res ISSN: 1226-8453 Impact factor: 6.060
Changes in Vienna test variables in reaction unit between red ginseng and placebo groups during the 2-week trial
| Reaction unit | Red ginseng | Placebo | Wilks Λ | |||
|---|---|---|---|---|---|---|
|
|
| |||||
| Baseline | 2 wk | Baseline | 2 wk | |||
|
| ||||||
| Median reaction time (msec) | 592.1 (101.2) | 544.8 (72.3) | 579.0 (92.9) | 604.2 (105.0) | 0.659 | 0.028 |
| Median decision time (msec) | 421.0 (63.5) | 392.6 (49.9) | 382.7 (64.8) | 417.2 (83.4) | 0.728 | 0.056 |
| Median motor time (msec) | 152.0 (25.1) | 145.1 (25.9) | 190.8 (44.3) | 173.2 (42.7) | 0.896 | 0.260 |
| Wrong decision | 0.13 (0.35) | 0.38 (0.52) | 0.00 (0.00) | 0.50 (0.55) | 0.959 | 0.487 |
| Right reaction | 8.00 (0.00) | 7.88 (0.35) | 7.67 (0.52) | 7.83 (0.41) | 0.854 | 0.178 |
| Incomplete reaction | 0.00 (0.00) | 0.13 (0.35) | 0.17 (0.41) | 0.00 (0.00) | 0.171 | 0.178 |
Values are given as mean (SD) scores.
Changes in Vienna test variables in motor performance series between red ginseng and placebo groups during the 2-week trial
| MPS | Red ginseng | Placebo | Wilks Λ | ||||
|---|---|---|---|---|---|---|---|
|
|
| ||||||
| Baseline | 2 wk | Baseline | 2 wk | ||||
|
| |||||||
| Right | Aiming error | 0.75 (1.17) | 1.50 (2.73) | 0.86 (0.90) | 0.57 (0.54) | 0.930 | 0.339 |
| Aiming H | 20.1 (0.4) | 20.3 (0.5) | 19.6 (0.8) | 20.0 (0.0) | 0.950 | 0.425 | |
| Aiming T | 6.57 (1.00) | 6.83 (1.04) | 6.41 (0.73) | 6.18 (0.75) | 0.855 | 0.161 | |
| Insertion long pins T | 37.2 (2.1) | 36.8 (4.2) | 40.6 (4.0) | 39.3 (3.9) | 0.988 | 0.698 | |
| Steadiness error | 1.00 (2.07) | 1.25 (1.04) | 3.71 (6.02) | 0.71 (1.11) | 0.874 | 0.194 | |
| Line tracking error | 18.0 (8.6) | 13.3 (6.0) | 18.9 (6.2) | 14.1 (5.7) | 1.0 | 0.993 | |
| Line tracking T | 27.6 (11.3) | 26.5 (8.9)5 | 26.3 (7.0) | 25.1 (13.5) | 1.0 | 0.984 | |
| Tapping H | 227.9 (23.4) | 225.5 (17.1) | 180.1 (37.7) | 191.6 (13.8) | 0.93 | 0.341 | |
| Inserting short pins T | 45.2 (5.9) | 47.3 (4.3) | 45.8 (5.4) | 52.4 (10.4) | 0.84 | 0.214 | |
| Left | Aiming error | 4.88 (5.22) | 3.00 (3.34) | 2.86 (2.27) | 4.14 (2.12) | 0.854 | 0.160 |
| Aiming H | 20.6 (1.5) | 20.1 (1.1) | 19.9 (0.4) | 19.7 (1.1) | 0.987 | 0.689 | |
| Aiming T | 9.59 (2.47) | 9.16 (1.65) | 8.18 (1.38) | 8.02 (1.93) | 0.992 | 0.758 | |
| Inserting long pins T | 44.1 (4.9) | 42.6 (6.2) | 43.4 (2.6) | 41.8 (5.0) | 1.0 | 0.963 | |
| Steadiness error | 1.38 (2.50) | 5.75 (9.30) | 0.71 (1.25) | 1.00 (1.92) | 0.862 | 0.173 | |
| Line tracking error | 26.4 (8.9) | 27.0 (5.3) | 28.4 (7.8) | 27.0 (5.3) | 0.983 | 0.643 | |
| Line tracking T | 26.3 (8.5) | 24.0 (6.5) | 24.8 (8.4) | 25.5 (12.8) | 0.953 | 0.436 | |
| Tapping H | 178.8 (28.6) | 175.8 (29.6) | 169.6 (33.8) | 182.3 (24.3) | 0.897 | 0.242 | |
| Inserting short pins T | 53.0 (11.3) | 55.0 (6.6) | 54.0 (5.4) | 51.3 (6.3) | 0.919 | 0.302 | |
| Both | Steadiness error (R) | 2.13 (4.85) | 0.88 (2.48) | 0.00 (0.00) | 3.57 (7.76) | 0.868 | 0.183 |
| Steadiness error (L) | 0.75 (1.17) | 0.63 (0.92) | 6.14 (15.4) | 2.86 (4.18) | 0.976 | 0.582 | |
| Inserting long pins T (R) | 57.5 (7.8) | 55.9 (6.0) | 62.0 (12.0) | 57.4 (6.1) | 0.962 | 0.487 | |
| Inserting long pins T (L) | 58.6 (8.9) | 56.5 (7.5) | 62.8 (11.7) | 58.5 (5.9) | 0.982 | 0.630 | |
| Aiming error (R) | 3.00 (2.93) | 2.13 (2.03) | 1.14 (1.68) | 1.00 (1.16) | 0.961 | 0.482 | |
| Aiming H (R) | 21.3 (1.0) | 20.3 (1.7) | 20.1 (1.2) | 20.0 (0.6) | 0.931 | 0.343 | |
| Aiming T (R) | 12.4 (3.8) | 12.3 (4.8) | 10.3 (1.5) | 9.8 (1.5) | 0.991 | 0.732 | |
| Aiming H (L) | 23.0 (4.9) | 20.9 (2.9) | 19.7 (1.6) | 18.3 (2.4) | 0.979 | 0.602 | |
| Aiming T (L) | 12.3 (3.6) | 13.0 (5.5) | 10.4 (1.6) | 9.8(1.6) | 0.925 | 0.324 | |
| Tapping H (R) | 188.1 (36.3) | 191.9 (33.1) | 172.4 (36.2) | 178.9 (27.5) | 0.991 | 0.734 | |
| Tapping H (L) | 174.9 (40.3) | 168.9 (22.9) | 173.7 (23.9) | 163.6 (32.6) | 0.985 | 0.668 | |
| Inserting short pins T (R) | 68.7 (15.8) | 66.9 (9.8) | 71.3 (11.9) | 75.2 (15.0) | 0.957 | 0.458 | |
| Inserting short pins T (L) | 68.4 (13.7) | 68.8 (9.5) | 73.7 (10.6) | 76.8 (15.2) | 0.988 | 0.703 | |
Values are given as mean (SD) scores.
H, number of hitting; T, time required for performance; R, right; L, left.
Changes in event-related potential test results between red ginseng and placebo groups during the 2-week trial
| Red ginseng | Placebo | Wilks Λ | ||||
|---|---|---|---|---|---|---|
|
|
| |||||
| Baseline | 2 wk | Baseline | 2 wk | |||
|
| ||||||
| Frontal | ||||||
| Fz latency | 369.29 (14.19) | 365.71 (18.54) | 361.07 (11.79) | 357.14 (12.57) | 1.0 | 0.975 |
| Fz amplitude | 6.23 (5.43) | 10.64 (3.89) | 6.84 (4.34) | 7.68 (3.32) | 0.863 | 0.193 |
| F4 latency | 368.57 (10.51) | 367.5 (13.63) | 354.29 (11.16) | 358.21 (11.47) | 0.975 | 0.586 |
| F4 amplitude | 7.48 (4.64) | 11.51 (4.11) | 7.05 (4.78) | 9.83 (3.76) | 0.980 | 0.632 |
| F3 latency | 366.43 (12.16) | 361.79 (14.86) | 362.14 (10.39) | 362.59 (14.58) | 0.962 | 0.501 |
| F3 amplitude | 6.74 (5.77) | 11.07 (4.36) | 7.05 (3.99) | 7.64 (2.45) | 0.788 | 0.098 |
| Mean (F3, F4, Fz) latency | 368.09 (10.9) | 365 (14.48) | 359.17 (9.78) | 359.29 (8.57) | 0.978 | 0.612 |
| Mean (F3,F4,Fz) amplitude | 6.74 (5.77) | 11.07 (4.36) | 6.98 (4.53) | 8.38 (3.26) | 0.883 | 0.230 |
| Central | ||||||
| Cz latency | 372.50 (13.5) | 367.14 (15.32) | 363.57 (13.55) | 355.71 (9.97) | 0.992 | 0.762 |
| Cz amplitude | 10.38 (5.83) | 13.2 (4.67) | 11.06 (5.08) | 10.81 (4.74) | 0.888 | 0.242 |
| C3 latency | 374.29 (12.59) | 367.5 (16.42) | 359.29 (14.25) | 363.21 (11.7) | 0.674 | 0.033 |
| C3 amplitude | 9.69 (5.61) | 13.1 (4.45) | 10.36 (4.64) | 10.44 (3.66) | 0.854 | 0.156 |
| C4 latency | 372.14 (13.59) | 368.57 (14.87) | 362.5 (14.14) | 367.5 (14.14) | 0.925 | 0.344 |
| C4 amplitude | 11.57 (4.67) | 14.24 (5.23) | 9.86 (5.06) | 10.53 (3.54) | 0.939 | 0.396 |
| Mean (C3, C4, Cz) latency | 372.98 (14.19) | 367.79 (16.71) | 361.79 (10.38) | 362.14 (7.13) | 0.920 | 0.327 |
| Mean (C3, C4, Cz) amplitude | 10.55 (5.71) | 13.51 (5.09) | 10.43 (5.33) | 10.6 (4.22) | 0.891 | 0.250 |
| Parietal | ||||||
| Pz latency | 372.14 (14.17) | 358.57 (11.29) | 367.5 (11.34) | 356.43 (9.62) | 0.998 | 0.888 |
| Pz amplitude | 14.21 (4.97) | 15.61 (6.13) | 11.73 (4.97) | 12.36 (4.49) | 0.994 | 0.801 |
| P3 latency | 372.14 (13.12) | 368.21 (9.79) | 367.14 (16.06) | 358.93 (8.22) | 0.987 | 0.697 |
| P3 amplitude | 13.44 (4.75) | 14.46 (4.47) | 11.60 (5.26) | 12.28 (3.32) | 0.999 | 0.897 |
| P4 latency | 370.36 (14.36) | 372.14 (10.3) | 365,36 (12.85) | 360 (12.89) | 0.966 | 0.526 |
| P4 amplitude | 13.51 (3.72) | 14.51 (6.71) | 510.31 (5.12) | 11.54 (3.98) | 0.999 | 0.938 |
| Mean (P3, P4, Pz) latency | 371.58 (14.89) | 366.31 (13.74) | 366.67 (11.93) | 358.45 (9.11) | 0.992 | 0.768 |
| Mean (C3, C4, Cz) amplitude | 13.72 (4.75) | 14.86 (6.14) | 11.21 (5.43) | 12.06 (4.18) | 0.999 | 0.919 |
Fig. 1.Voltage difference between red ginseng and placebo group at baseline (A) and after 2 wk (B). The red ginseng group showed a greater-decreased in P300 voltage difference from baseline compared with that of the placebo group during 2-week trial period (at time=[0.30-0.35], red circle), according to brain mapping.
Changes in Vienna test variables in vigilance between red ginseng and placebo groups during the 2-week trial
| Vigilance | Red ginseng | Placebo | Wilks Λ | |||
|---|---|---|---|---|---|---|
|
|
| |||||
| Baseline | 2 wk | Baseline | 2 wk | |||
|
| ||||||
| No. of correct | 99.3 (1.0) | 92.1 (17.9) | 98.7 (1.7) | 97.3 (2.9) | 0.949 | 0.416 |
| Mean value of reaction time (s) | 0.45 (0.06) | 0.48 (0.08) | 0.53 (0.12) | 0.53 (0.14) | 0.965 | 0.507 |
| No. of incorrect | 0.50 (1.41) | 1.13 (2.80) | 1.00 (0.58) | 0.71 (1.11) | 0.873 | 0.192 |
| No. of missed | 0.71 (1.11) | 1.57 (1.40) | 1.29 (1.70) | 2.71 (2.87) | 0.966 | 0.529 |
Values are given as mean (SD) scores.